Better Therapeutics, Inc. (BTTX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. David P. Perry M.B.A.
|
Co-Founder & Executive Chairman | 110.67k | -- | 1968 |
|
Mr. Frank L. Karbe M.B.A.
|
Interim CFO | 500k | -- | 1968 |
|
Dr. Mark A. Berman M.D.
|
Chief Medical Officer | 425k | -- | 1976 |
|
Ms. Kristin Wynholds
|
Chief Product Officer | 390k | -- | 1973 |
|
Mr. Andres Camacho
|
Senior VP of Technology & Head of Engineering | -- | -- | -- |
|
Ms. Angela Willis
|
Senior Vice President of Market Access | -- | -- | -- |
|
Ms. Jessica Meng
|
Chief Commercial Officer | -- | -- | 1975 |
Better Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 54
Description
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
May 30, 2024 at 12:00 AM UTC
15-12G: Notice of termination of registration of a class of securities under Section 12(g)
May 23, 2024 at 12:00 AM UTC
POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
